[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590340":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":22,"responsibleParty":39,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Fudan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients received SG",null,"HER2-negative breast cancer patients who received SG in the advanced stage",[13],{"name":14,"affiliation":5,"role":15},"Jian Zhang, MD,PhD","PRINCIPAL_INVESTIGATOR",[17],{"name":14,"role":18,"phone":19,"phoneExt":20,"email":21},"CONTACT","+8664175590","85000","syner2000@163.com",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Fudan University Shanghai Cancer Center","RECRUITING","Shanghai","Shanghai Municipality","200032","China","CN",{"type":32,"coordinates":33},"Point",[34,35],121.45806,31.22222,{"lat":35,"lon":34},[38],{"name":14,"role":18,"phone":19,"phoneExt":20,"email":21},{"type":15,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jian Zhang,MD","Professor","100590340","a-real-world-study-of-sacituzumab-govitecan-100590340",false,"NCT06966141","A Real World Study of Sacituzumab Govitecan","A Real World Study: Clinical Outcomes and Safety of Sacituzumab Govitecan in Metastatic HER-2 Negative Breast Cancer Patients","Inclusion Criteria:\n\n1. Male or female aged 18 or above;\n2. The Eastern Cooperative Oncology Group (ECOG) physical condition score of the United States is ≤2;\n3. Unresectable or metastatic triple-negative breast cancer confirmed by tumor histology or cytology, and having received at least two systemic treatments previously (at least one of which was for metastatic disease); Or HR+\u002FHER2- (IHC 0, 1+ or IHC 2+\u002FISH-) unresectable or metastatic breast cancer confirmed by tumor histology or cytology, with previous endocrine therapy and ≥2 lines of systemic therapy (for metastatic disease);\n4. Receive gosatetuzumab treatment in the advanced stage;\n5. During the study period, voluntarily abide by this trial protocol and receive regular follow-ups;\n6. All women of childbearing age, fertile men or their spouses who have no plans for fertility or sperm donation throughout the trial period until 6 months after the last dose, or who voluntarily take effective contraceptive measures.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Those with acute or chronic infections, or those with other serious diseases at the same time, are judged by the researchers as unsuitable for this study;\n3. Having suffered from other malignant tumors within 5 years (excluding the following situations: cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and papillary thyroid carcinoma; A second primary cancer that has been completely cured and has no recurrence within five years; Researchers have clearly identified which primary tumor source the metastatic foci belong to.\n4. Those with mental illness or mental disorders, poor compliance and inability to cooperate and describe treatment responses;\n5. Those with severe organic diseases or major organ failure, such as decompensated heart, lung, liver or kidney failure, which makes them unable to tolerate treatment;\n6. Patients allergic to gosatetuzumab;\n7. Patients who changed their treatment regimens after gosatetuzumab treatment due to non-disease progression reasons;\n8. The researcher believes that the patient has other circumstances that make them unsuitable for participating in this study.","ALL","18 Years",{"count":52,"type":53},100,"ESTIMATED","OBSERVATIONAL","Clinical Outcomes and Safety of Sacituzumab Govitecan in Metastatic HER-2 negative Breast Cancer Patients",[57,58],"Breast Cancer Metastatic","Treatment Outcome","2025-05-02",{"date":61,"type":62},"2025-05-11","ACTUAL",{"date":64,"type":62},"2024-08-12",{"date":66,"type":53},"2027-08-01",{"name":5,"class":6},1]